{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloablative+Conditioning&page=2",
    "query": {
      "condition": "Myeloablative Conditioning",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloablative+Conditioning&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T07:32:19.667Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01690520",
      "title": "Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia in Remission",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Nohla Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "6 Months to 65 Years"
      },
      "enrollment_count": 163,
      "start_date": "2012-12-11",
      "completion_date": "2020-05-29",
      "has_results": true,
      "last_update_posted_date": "2021-07-06",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Palo Alto, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01690520"
    },
    {
      "nct_id": "NCT03734601",
      "title": "Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Myeloproliferative Disorder",
        "Chronic Lymphocytic Leukemia",
        "B-cell Lymphoma",
        "T-cell Lymphoma",
        "Non Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Total body irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Total lymphoid irradiation (TLI)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2018-11-05",
      "completion_date": "2020-11-17",
      "has_results": true,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03734601"
    },
    {
      "nct_id": "NCT02057770",
      "title": "Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "total-body irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Stem cell transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2014-02-28",
      "completion_date": "2018-03-23",
      "has_results": false,
      "last_update_posted_date": "2018-10-12",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057770"
    },
    {
      "nct_id": "NCT01592045",
      "title": "ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "ch14.18 -NCI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ch14.18-UTC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin (IL-2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Isotretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "Up to 8 Years"
      },
      "enrollment_count": 28,
      "start_date": "2012-08",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2015-09-23",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01592045"
    },
    {
      "nct_id": "NCT01183429",
      "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "3F8 and 13-cis-retinoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Months and older"
      },
      "enrollment_count": 39,
      "start_date": "2010-08-12",
      "completion_date": "2018-09-13",
      "has_results": true,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183429"
    },
    {
      "nct_id": "NCT00481832",
      "title": "Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "BCNU",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Antithymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Autologous hematopoietic stem cell transplantation (auto-HSCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Total lymphoid irradiation",
          "type": "PROCEDURE"
        },
        {
          "name": "CD34+ Cells",
          "type": "DRUG"
        },
        {
          "name": "Solu-Medrol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2007-01",
      "completion_date": "2017-03-30",
      "has_results": true,
      "last_update_posted_date": "2018-02-14",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00481832"
    },
    {
      "nct_id": "NCT00460421",
      "title": "A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Palifermin",
          "type": "DRUG"
        },
        {
          "name": "Total Body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "1 Year to 16 Years"
      },
      "enrollment_count": 27,
      "start_date": "2006-08",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2014-12-05",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 7,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00460421"
    },
    {
      "nct_id": "NCT00064311",
      "title": "Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Infection",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "ravuconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-06",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064311"
    },
    {
      "nct_id": "NCT00134004",
      "title": "Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "6 Months to 74 Years"
      },
      "enrollment_count": 210,
      "start_date": "2004-10",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2015-10-06",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134004"
    },
    {
      "nct_id": "NCT04339101",
      "title": "Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Hematologic and Lymphocytic Disorder",
        "Myelodysplastic Syndrome",
        "Primary Myelofibrosis",
        "Secondary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Itacitinib Adipate",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 59,
      "start_date": "2020-11-11",
      "completion_date": "2025-10-09",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-06-11T07:32:19.667Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04339101"
    }
  ]
}